FDA's Breakthrough Therapy Designation to PKC412 (Midostaurin) for AML. Issue 6 (25th March 2016)

Record Type:: Journal Article
Title:: FDA's Breakthrough Therapy Designation to PKC412 (Midostaurin) for AML. Issue 6 (25th March 2016)
Main Title:: FDA's Breakthrough Therapy Designation to PKC412 (Midostaurin) for AML
Authors:: N/A,
Abstract:
Is Part Of:: Oncology times. Volume 38:Issue 6(2016:Mar.)
Journal:: Oncology times
Issue:: Volume 38:Issue 6(2016:Mar.)
Issue Display:: Volume 38, Issue 6 (2016)
Year:: 2016
Volume:: 38
Issue:: 6
Issue Sort Value:: 2016-0038-0006-0000
Page Start:
Page End:
Publication Date:: 2016-03-25
Subjects:: Oncology -- Periodicals
Cancer -- Periodicals
Cancer
Oncology
Periodicals
616.944
Journal URLs:: http://www.oncology-times.com/ ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.COT.0000482237.71213.3c ↗
Languages:: English
ISSNs:: 0276-2234
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 6256.984000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 939.xml